Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Mark Wildgust
Person

Mark Wildgust

Tracked across 1 events · 6 articles · First seen May 31, 2026 · Last active Jun 02, 2026

Sentiment
0
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 0
Tech
J&J Erleada improves prostate cancer outcomes
Impact: Mark Wildgust>>>, Johnson & Johnson>>>'s medical affairs lead for oncology, affirmed the unequivocal patient benefit of Apalutamide>>>.
May 31, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Mark Wildgust live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.